<DOC>
	<DOCNO>NCT00432562</DOCNO>
	<brief_summary>This study randomize , single dose crossover comparison investigational product Reference Product ( vinorelbine tartrate injection , NAVELBINEÂ® ) . The primary objective demonstrate equivalence ANX-530 Reference Product , NAVELBINE .</brief_summary>
	<brief_title>A Bioequivalence Study Vinorelbine Tartrate Injectable Emulsion Patients With Advanced Cancer .</brief_title>
	<detailed_description>ANX-530 ( vinorelbine tartrate injectable emulsion ) , investigational drug , oil-in-water emulsion vinorelbine tartrate compose oil phase emulsifier disperse aqueous solution . ADVENTRX Pharmaceuticals , Inc. San Diego , California , develop ANX-530 vinorelbine tartrate formulation use clinical setting Vinorelbine Tartrate Injection ( NAVELBINE ) indicate . Nonclinical toxicology study suggest either equivalent less toxicity ANX-530 compare Reference Product . In particular , ANX-530 cause less vein toxicity rabbit vein irritation model , suggest ANX-530 could potentially cause less venous irritation NAVELBINE clinical setting . ADVENTRX investigate whether ANX-530 could substitute NAVELBINE setting .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Age &gt; 18 year . Advanced cancer potentially sensitive vinorelbine : Breast cancer . Stage 3 4 nonsmall cell lung cancer . NonHodgkins lymphoma . Cancer histologic type , sensitive vinca alkaloid . Rare tumor type standard treatment , single agent vinorelbine appropriate therapy . Failure standard treatment ( ) tumor . Life expectancy least three month . ECOG performance level 02 Karnofsky score 10070 . Hematological serum chemistry result define range . Willingness ability provide write informed consent . Pregnancy lactation . In woman childbearing potential , positive pregnancy test result , pregnancy test result , use reliable contraception , baseline . A postmenopausal woman consider childbearing potential amenorrhea least 12 consecutive month . Previous treatment vinorelbine mitomycin . Any history suggest demonstrate resistance , lack response , intolerance prior vinca alkaloid treatment . Active infection . Prior anticancer therapy complete within four week prior first day study treatment . Failure recover toxicity previous cancer treatment ( patient alopecia exclude ) . Participation another experimental drug study within four week prior first day study treatment . Requirement concomitant chemotherapeutic agent study medication . Any investigator judgment individual would appropriate study subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>